Dermatol. praxi. 2024;18(4):202-205 | DOI: 10.36290/der.2024.040

Dupilumab and prurigo nodularis in hepatopathy

MUDr. Eva Březinová, Ph.D.
I. dermatovenerologická klinika FN u sv. Anny v Brně, Lékařská fakulta Masarykovy univerzity v Brně

The case report describes a 67-year-old female patient with long-lasting severe prurigo nodularis, which arose in association with hepatopathy. Due to this comorbidity, the options for systemic therapy were limited. Dupilumab proved to be an effective and safe treatment in this patient. The effect of dupilumab on liver metabolism and regeneration has not yet been fully investigated. In practice, however, there are no recorded cases of liver function deterioration or even liver failure following this drug.

Keywords: prurigo nodularis, hepatopathy, biological treatment, dupilumab.

Accepted: November 6, 2024; Published: November 22, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Březinová E. Dupilumab and prurigo nodularis in hepatopathy. Dermatol. praxi. 2024;18(4):202-205. doi: 10.36290/der.2024.040.
Download citation
PDF will be unlocked 22.11.2025

References

  1. Marani M, Madan V, Le TK, et al. Dysregulation of the Skin-Liver Axis in Prurigo Nodularis: An Integrated Genomic, Transcriptomic, and Population-Based Analysis. Genes (Basel). 2024;15(2):146. Go to original source... Go to PubMed...
  2. Paganini C, Talamonti M, Maffei V, et al. Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks. J Clin Med. 2024;13(3):878. Go to original source... Go to PubMed...
  3. Goh YP, Henderson NC, Heredia JE, et al. Eosinophils secrete IL-4 to facilitate liver regeneration. Proc Natl Acad Sci U S A. 2013;110(24):9914-9. Go to original source... Go to PubMed...
  4. Weng SY, Wang X, Vijayan S, et al. IL-4 Receptor Alpha Signaling through Macrophages Differentially Regulates Liver Fibrosis Progression and Reversal. EBioMedicine. 2018;29:92-103. Go to original source... Go to PubMed...
  5. Ly K, Smith MP, Thibodeaux Q, et al. Dupilumab in patients with chronic hepatitis B on concomitant entecavir. JAAD Case Rep. 2019;5(7):624-626. Go to original source... Go to PubMed...
  6. Mota F. Atopic Dermatitis Patient With Hepatitis C Treated With Dupilumab-A Case Report. Actas Dermosifiliogr. 2024;115(4):T420-T421. Go to original source... Go to PubMed...
  7. Drucker AM, Lam M, Flohr C, et al. Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey. Dermatitis. 2022;33(3):200-206. Go to original source... Go to PubMed...
  8. Dupixent in AD, European Public Assessment Report. Sanofi-aventis groupe; July 2017, accessed via, last access on 13. 05. 2022. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/004390/WC500236509.pdf.
  9. Čapková Š. Těžká forma atopické dermatitidy u chlapce po transplantaci jater a dvou následných retransplantacích. Dermatol. praxi. 2022;16(3):153-156. Go to original source...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.